Long-term clinical outcomes of radical prostatectomy versus watchful waiting in localized prostate cancer patients: A systematic review and meta-analysis by Nouhi, M. et al.
 
 
Iran J Public Health, Vol. 48, No.4, Apr 2019, pp.566-578                                                    Review Article 
566                                                                                                        Available at:    http://ijph.tums.ac.ir 
 
 
Long-Term Clinical Outcomes of Radical Prostatectomy versus 
Watchful Waiting in Localized Prostate Cancer Patients: A  
Systematic Review and Meta-Analysis 
 
Mojtaba NOUHI 1,2, Seyed Masood MOUSAVI 2, Alireza OLYAEEMANESH 1,3, Nasser 
SHAKSISALIM 4, *Ali AKBARI SARI 5 
 
1. Health Equity Research Center, Tehran University of Medical Sciences, Tehran, Iran 
2. Department of Health Service Management, School of Health Management and Information Sciences, Iran University of Medical 
Sciences, Tehran, Iran 
3. National Institute for Health Research, Tehran University of Medical Sciences, Tehran, Iran 
4. Department of Urology, Shahid Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran 
5. Department of Health Management & Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran 
 
*Corresponding Author: Email: akbarisari@tums.ac.ir 
 







Background: The present study aimed to compare the long-term clinical and functional outcomes of patients 
with clinically localized prostate cancer treated with radical prostatectomy compared to the watchful waiting. 
Methods: PubMed, Cochrane Central Register of Controlled Trials and reference lists of relevant marker 
studies were scrutinized from inception to Jan 2018. Two reviewers conducted data abstraction and quality 
assessment of included trials independently. Quality of included studies were assessed by using Cochrane 
checklist. Inverse-variance and Mantel-Haenszel estimates under random effects model were used to pool re-
sults as relative risks with 95% confidence interval. Heterogeneity was assessed by using I2. 
Results: Three randomized controlled trials with 1568 participants were included. Compared to watchful 
waiting, radical prostatectomy had no significant effect on all-cause mortality at 12-year follow-up. However, 
radical prostatectomy had significant effect on reducing prostate-cause mortality at 12-year follow-up. We 
found significant lower prostate-cause mortality in patients with PSA>10 and GS≥7 scores who had under-
gone radical prostatectomy compared with patients in watchful waiting group. In addition, younger patients 
undergoing surgery developed lower distant metastases rate compared to another approach. Watchful waiting 
had a significant effect on erectile and urinary incontinence during 2 years. 
Conclusion: There was no significant difference between radical prostatectomy and watchful waiting on all-
cause mortality. However, the radical prostatectomy was associated with statistically lower prostate-cause mor-
tality and metastases rates. Compared with older men, younger men experienced better clinical outcomes. 
Moreover, watchful waiting had better effect on reducing erectile dysfunction and urinary incontinence among 
patients during 2 years compared to radical prostatectomy. 
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Introduction 
 
Prostate cancer is well-known as the second most 
diagnosed cancer of the men and the fifth most 
common cancer worldwide (1). Most of the de-
veloped and developing countries have also en-
countered increasing prevalence of the prostate 
cancer. Population aging (2, 3) and implementa-
tion of screening (4-7), on one hand, and some 
clinical characteristics of the prostate cancer such 
as the prolonged natural history (8, 9); on the 
other hand, have contributed to an increase in 
the number of clinically localized prostate cancer 
patients. As a result, these have incurred tremen-
dous burden of the prostate cancer and its side-
effects on the communities (10-13).  
Hence, managing clinically localized prostate can-
cer to prevent unnecessary treatment, obtaining 
the highest benefit of the interventions and sim-
ultaneously preserving the value of the money in 
health care sector have become crucial issues for 
professionals and policy makers (14, 15). While 
surgery and conservative management known as 
two medical strategies are used for clinically local-
ized prostate cancer patients, both have had dif-
ferent clinical and functional outcomes over time.  
Many studies, though with different methods and 
qualities, have attempted to represent clinical and 
functional outcomes of the interventions (16-21). 
However, recently, few well-designed studies 
have compared long-term outcomes of radical 
prostatectomy (RP) against watchful waiting 
(WW) and some valuable reports have published 
in this regard. Combining these findings with me-
ta-analysis helps to clarify some ambiguities and 
answer some controversies about the long-term 





Data sources and searches 
We used comprehensive search strategies to iden-
tify reports of randomized controlled trials in-
dexed in PubMed and The Cochrane Library 
from inception to Jan 2018. The language of pub-
lication was not limited to English, though. In 
addition, clinicaltrial.gov (https://clinicaltrials.gov) 
website and the reference lists of selected studies 
were searched to find other relevant trials. After 
pooling the retrieved papers and removing dupli-
cates, two reviewers (MN & AAS) screened Title 
and Abstract of searched paper independently to 
select potentially eligible papers. Then, they read 
full text of the selected papers to exclude non-
eligible papers and include qualified randomized 
controlled trials reports based on predetermined 
criteria. Any discrepancies raised between review-




We included randomized controlled studies 
which compared RP with WW in treatment of 
men who would suffer from localized prostate 
cancer (<T2, N0, M0). Having defined RP as 
procedure of removing entire prostate gland and 
some surrounding tissues by any procedure (e.g. 
perineal, laser, retropubic, laparoscopic, robotic), 
we also dubbed WW as any conservative ap-
proach to manage clinically localized prostate 
cancer which postpones initial treatment until 
unfavorable changes appear in clinical, pathologi-
cal or biochemical features of the patients. Over-
all mortality was assigned as primary outcome. 
Other prognosis outcomes such as disease-
specific mortality, local progression and metasta-
ses as well as sexual, urinary, bowel and psycho-
logical functions were assigned as the secondary 
outcome.  
 
Data extraction and quality assessment 
A data abstraction form was developed and the re-
viewers extracted the outcomes of interest from 
selected studies. Any controversy between review-
ers was discussed with the third author (NS) to at-
tain consensus. General information (authors, title, 
journal of publication, date of publication), study 
population characteristics (age, race, stage, grade, 
prostate-specific-antigen level, gleason score, meth-
od of detection), study design details (sample size 
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and source of funding) and study results (prede-
fined clinical or health-related quality-of life out-
comes) were, also, extracted. To assess quality of 
selected studies and risk of biases, the Cochrane 
method was used. We, subsequently, appraised ran-
domization allocation, allocation concealment, 
blinding of outcome assessment, incomplete out-
come data and selective report. In addition, sample 
size and funding source were taken into account.  
 
Data synthesis and analysis  
We compared clinical effects of RP and WW to 
manage clinically localized prostate cancer. The 
RR was used as the principal measure to summa-
rize clinical effect of the treatments on all out-
comes. When the rates of event in participants of 
the study arm was available, we applied Mantel-
Haenszel method. However, when the preferred 
information was not available, inverse-variance 
method was used consequently (22). To calculate 
pooled estimate of RR with 95% confidence in-
terval, we applied fixed effects and random ef-
fects models. To assess heterogeneity, I2 test was 
used in which I2 >50% represents heterogeneity 
between studies. If heterogeneity of the studies 
was not significant, we would report the fixed 
effects estimation. Subgroup analyses were per-
formed regarding age (<65≥ years). According to 
Cochrane method, disclosing publication bias 
through the Funnel plot was not reasonable for 
<10 included studies (22). Calculations of meta-





A total of 8921 studies were retrieved through 





Fig. 1: Flowchart of identification and selection of included trials 
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After removing duplicates, summaries of 8864 
studies were screened by the reviewers. Then, 
they scrutinized the full texts of the remaining 89 
studies. The main reason for exclusion was non-
randomized controlled studies (n=57). The re-
maining studies did not have either one of the 
predefined medical strategies (n=13) or sufficient 
original data (n=4). Ultimately, thirteen papers 
derived from three trials met inclusion criteria to 
be included in the study. Two of them had been 
conducted in United States-Prostate cancer In-
tervention versus Observation Trial (PIVOT) 
and the Veterans Administration Cooperative 
Urological Research Group (VACURG) - and the 
third in Scandinavia, Scandinavian Prostate Can-
cer Group-4 called (SPCG-4). Table 1 summariz-
es characteristics of included trials. Overall, 1568 
men had participated in the included trials in 
which 785 of them undergone RP and remaining 
783 men were allocated to WW arm. The year of 
reporting included trials ranged between 1981 
and 2012, spanning 31 years.  
 
Table 1: Characteristics of trials included in the study 
 
Name of trial SPCG-4 PIVOT VACURG 
Location Scandinavian countries₮ United States United States 
Setting 14 centers 52 sites 19 hospitals 
Enrollment timeframe From October 1989 to Feb-
ruary 1999 
From November 1994 to 
January 2002 
From May 1967 to March 
1975 
Participants RP=347 WW=348 RP=364 WW=367 RP₴=74 WW₵=68 
Mean age (year) 64.7 Sixty seven RP =62.7 
WW=66 
 
Race %(Black, White, other) NM RP (30.5,63.7,5.9) 
WW(33, 60. 7.1) 
NM 
PSA detected prostate cancer 
(%) 
five Seventy six (enrollees) NM 
GS distribution 
(GS<7, GS≥7, unknown) 
RP₳(60.6, 26.2, 13.3) 
WW(60.9, 29.6, 9.5) 
 
WW(74.6, 24.5, 0.9) 
RP(71.6, 28.2, 0.2) 
RP(87,11, 2,) 
Placebo(86, 8, 6) 







Main outcome Prostate-cancer-mortality All-cause mortality Time to progression₫ 
Follow-up schedule Twice a year for the first two 
years and then annually 
Twice a year at minimum 
of 8 years , maximum of 15 
years or patient’s death 
Twice a year until 1978 and 
then stopped 
Subgroup analysis Age, GS, PSA Age, race, PSA, tumor 














Gleason Score/ Prostate-Specific-Antigen/NR: did not mention in trial’s reports /₳ More than 100% refers to rounding deci-
mal numbers which reported in original papers/₫ includes first metastases, rising acid phosphates to twice normal or death due 
to the prostate cancer, then overall survival was added/₢ some curative treatments also recommended in the protocol/₮ it is 
included Sweden, Finland and Iceland countries/₴ the strategy consists RP+ oral placebo/₵ the strategy consists oral placebo 
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The VACURG, PIVOT and SPCG-4 investiga-
tors have reported their findings in four (23-26), 
one (27) and eight (28-35) publications. PIVOT 
and SPCG-4 trials compared RP with WW; while 
VACURG trial compared RP plus oral placebo 
with oral placebo alone. SPCG-4 investigators 
have reported all-cause death, disease-specific 
death, local progression and metastases of ran-
domized participants during five (30, 32), eight 
(32), ten (30, 33), twelve (29) and fifteen (28) 
years. They, analyzed effect of age on clinical 
outcomes. Furthermore, functional outcomes 
(urinary, sexual and bowel) and psychological sta-
tus were analyzed over time (31, 34, 35). PIVOT 
investigators reported all-cause and disease-
specific mortalities and bone metastases at 4, 8 
and 12 years follow-up according to race (white, 
black or other), age (65<years≥65), Gleason 
score (<7≥), PSA level (≤10>), risk of tumor 
(low, intermediate and high), Charlson index 
score (0 vs. ≥1) and self-report performance sta-
tus (0 vs. 1-4) (27). VACURG investigators re-
ported all-cause mortality after fifteen (25) and 
twenty three (26) years follow-up regardless of 
subgroup characteristics. Following the partici-
pants in all trials began similarly, twice a year, but 
they had experienced different follow-up plan. 
SPCG-4 trial underwent yearly follow-up after 
two years (32), VACURG trial continued until 
1978 (23) and PIVOT also pursued this process 
for the years or patient’ death (36). PSA-detected 
percentage and mean age of participants relatively 
varied between the trials. PIVOT was a unique 
trial in which sufficient attention was paid to race 
differences (36). 
 
Assessment the quality of studies 
Among included trials, PIVOT and SPCG-4 
proved to have adequate randomization and con-
cealment of allocation within treatments. Ran-
domization in PIVOT and SPCG-4 was stratified 
based on site/center using telephone services (32, 
36). SPCG-4 was also stratified based on the de-
gree of differentiation in the grade of cancer 
while VACURG mentioned neither randomiza-
tion process nor concealment of allocation. Re-
garding the nature of study arms, blinding the 
patients was not possible. Blinding the assessors 
who analyzed the outcomes to prevent selection 
bias was clearly reported in SPCG-4 and PIVOT 
trials, however, it was not reported in the 
VACURG trial whether they were blinded (32, 
36). All trials but the VACURG used intention-
to-treatment approach to analyze the outcomes. 
In addition, investigators in PIVOT and SPCG-4 
trials reported power of the sample in their re-
ports, while we found no explanation about sam-
ple size and its power in the VACURG trial. 
Thus, the VACURG was judged to represent no 
reliable evidence compared with the other select-
ed trials. Table 2 provides a picture to compara-
tively observe the methodological quality of se-
lected trials.  
To provide meta-analysis of the same outcomes 
with same time-point, PIVOT and SPCG-4 trials 
implied the following outcomes: all-cause mortal-
ity, prostate-cancer mortality, distant metastases 
and their subgroup analyses of age at 12 years 
follow-up; urinary incontinence and erectile dys-
function at 2 years follow-up. Clinical and func-
tional outcomes data of the PIVOT data were 
extracted from Wlit 2012 (27). Regarding the 
SPCG-4, we extracted clinical outcomes data 
from Bill-Axelson 2008 (30) and functional out-
comes from Johansson 2009 (34). Individual 
functional outcomes of SPCG-4 were collected at 
2-year follow-up. The VACURG trial was of no 
sufficient quality to be included in the pooled 
estimation of the outcomes. Table 3 provides a 
summary of the following calculations. 
 
Meta-analysis findings 
All-cause mortality  
Using the Inverse-Variance method, no signifi-
cant difference was observed between treatments, 
RR 0.89 [0.78 to 1.02; P=0.1 I2=0%] (Fig. 2). In 
subgroup analysis we found no significant effect 
of the treatments on reducing all-cause death 
among men of <65 years age, RR 0.78 [0.60 to 
1.01] P=0.32. I2=90%, and ≥65 years with RR 
0.93 [0.80 to 1.09] P=0.36 I2=0%. 
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Table 2: Methodological quality of included trials 
 
Name SPCG-4 PIVOT VACURG 
Randomization allocation (SB) Adequate Adequate Unclear risk 
Allocation concealment (SB) Adequate Adequate Unclear risk 
Blinding of outcome assessment 
(SB) 
Adequate Adequate Unclear risk 
Incomplete outcome data (AB) Adequate Adequate Inadequate₳ 
Selective report(RB) Adequate Adequate Unclear risk 
Other bias₢ Adequate Adequate Inadequate₳ 
Sample power 85% power to detect a 25% 
relative reduction in all-cause 
mortality 
85% power to detect a 25% 
relative reduction in all-cause 
mortality 
NM 
Analysis approach Intention-to-treatment Intention-to-treatment NM 
Randomization strategies A telephone service at office 
outside the clinical units 
Central interactive telephone 
system 
NM 
Stratification in randomization According to degree of differ-
entiation in cancer grade and 
center 
According to sites NM 




₰ If no notable bias exist which effect on results of trial/ ₳ if there was a great bias which make misleading on results of trial/₫ 
if no sufficient data reported to assess the studies/NM: not mention in trial’s reports/SB: selection bias/AB: attrition bias/RB: 
reporting bias/₢ some biases that did not include in the category 
 
Table 3: Summaries of pooled effects of treatment in different outcomes 
 
Outcome Subgroup Studies Statistical method Pooled effect  
estimate 





ity at 12 years 
All patients 2 Risk Ratio (IV, Fixed, 
95% CI) 
0.89 (0.78 to 1.02) Z= 1.67 
P(Z)= 0.1 
0 
Age< 65 years 2 Risk Ratio (IV, Ran-
dom, 95% CI) 
0.78 (0.60 to 1.01) Z= 0.99 
P(Z)= 0.32 
90 
Age ≥65 years 2 Risk Ratio (IV, Fixed, 
95% CI) 




mortality at 12 
years 
All patients 2 Risk Ratio (IV, Fixed, 
95% CI) 
0.60 (0.38 to 0.94) Z= 2.22 
P(Z)=0.03 
0 
Age<65 years 2 Risk Ratio (IV, Fixed, 
95% CI) 
0.46 (0.27 to 0.76) Z= 2.99 
P(Z)= 0.003 
0 
Age ≥65 years 2 Risk Ratio (IV, Fixed, 
95% CI) 
0.87 (0.56 to 1.34) Z=0.63 
P(Z)= 0.53 
0 
PSA>10 2 Risk Ratio (IV, Fixed, 
95% CI) 
0.61 (0.38 to 0.98) Z=2.05 
P(Z)= 0.04 
0 
PSA≤10 2 Risk Ratio (IV, Fixed, 
95% CI) 
0.77 (0.44 to 1.36) Z=0.92 
P(Z)= 0.36 
0 
Gleason<7 2 Risk Ratio (IV, Fixed, 
95% CI) 
0.61 (0.35 to 1.06) Z=1.76 
P(Z)= 0.08 
0 
Gleason≥7 2 Risk Ratio (IV, Fixed, 
95% CI) 




ses at 12 years 
All patients 2 Risk Ratio (IV, Fixed, 
95% CI) 
0.55 (0.36 to 0.85) Z= 2.72 
P(Z)= 0.007 
44 
Age<65 years 2 Risk Ratio (IV, Fixed, 
95% CI) 
0.53 (0.36 to 0.78) Z= 3.18 
P(Z)= 0.001 
0 
Age ≥65 years 2 Risk Ratio (IV, Ran-
dom, 95% CI) 




tion at 2 years 
All patients 2 Risk Ratio (M-H, 
Fixed, 95% CI) 




nence at 2 years 
All patients 2 Risk Ratio (M-H, 
Fixed, 95% CI) 
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Fig. 2: Pooled estimates of all-cause mortality of RP versus WW in patients with localized prostate cancer 
 
Prostate-cancer mortality  
Using Inverse-Variance method, disease-specific 
death revealed a significant difference between 
the treatments, RR 0.60 [0.38 to 0.94; P=0.03]. 
Risk difference was -0.036 [-0.066 to -0.007]. 
There was no heterogeneity between trials (I2= 
0%). Moreover, the number needed to treat to 
avert one prostate-cause death was 25. 
Using Inverse-Variance method, patients of <65 
years demonstrated a significant difference favor-
ing RP, RR 0.46 [0.27 to 0.76; P=0.003] I2= 0%. 
Risk difference was -0.06 [-0.112 to -0.012]. The 
number needed to treat to avert one prostate-
cause death among younger patients was 16. For 
patients of ≥65 years, results suggested a similar 
clinical effect of treatments, RR 0.87 [0.56 to 
1.34; P=0.53]. Additionally, there was no hetero-
geneity between trials (I2= 0%).  
Disease-specific death in patients with PSA>10 
was significantly lower in RP group that WW 
group, RR 0.61 [0.38 to 0.98; P=0.04]. There was 
no heterogeneity between trials (I2= 0%).But in 
patients with PSA≤10 number of disease-specific 
death between two groups was not significant, 
RR 0.77 [0.44 to 1.34; P=0.36]. There was no 
heterogeneity between trials (I2= 0%). 
Disease-specific death in patients with 
Gleason≥7 was significantly lower in RP group 
that WW group, RR 0.56 [0.34 to 0.92; P=0.02]. 
There was no heterogeneity between trials (I2= 
0%).But in patients with Gleason<7 number of 
disease-specific death between two groups was 
not significant, RR 0.61 [0.35 to 1.06; P=0.08]. 
There was no heterogeneity between trials (I2= 
0%). Figure 3 represents the forest plot of pros-
tate-cancer death and its subgroup results.  
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Fig. 3: Pooled estimates of prostate-specific mortality of RP versus WW in patients with localized prostate cancer 
 
Distant metastases 
Using inverse-variance method, distant metasta-
ses rate showed significant difference favoring 
RP, RR 0.55 [0.36 to 0.85; P=0.006] I2= 44% risk 
difference -0.060 [-0.092 to -0.028]. The number 
needed to treat to avert one distant metastasis 
was 16. In patients with <65 years, it demonstrat-
ed significant lower rate favoring RP, RR 0.53 
[0.36 to 0.78; P=0.001] I2= 0% risk difference -
0.059 [-0.115 to -0.004]. The number needed to 
treat to avert one distant metastasis among 
younger patients was 16. But we found no signif-
icant difference between treatments among men 
aged ≥65 years, RR 0.55 [0.23 to 1.30; P=0.17] I-
2= 72%. Figure 4 shows forest plot of distant me-
tastases and its subgroups. 
 
Urinary incontinence 
We applied Mantel-Haenszel method and found 
significant difference among participants in favor 
of WW group at 2 years follow-up, RR 2.95 [1.91 
to 4.56 P<0.00001] risk difference -0.138 [-.189 
to -0.088]. The number needed to treat to avert 
one the outcome was 7. There was no heteroge-
neity between trials (I2= 0%). The Fig. 5 illus-
trates the results. 
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Fig. 5: Pooled estimates of urinary incontinency and erectile dysfunction outcomes of RP versus WW in patients 
with localized prostate cancer 
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Erectile dysfunction 
Our result represented significant difference 
among participants in favor of WW group at 2 
years follow-up, RR 1.88 [1.65 to 2.15; 
P<0.00001] risk difference -0.378 [-0.446 to -
0.310]. The number needed to treat to avert one 
erectile dysfunction was 2. Mantel-Haenszel 
method was used. There was no heterogeneity 
between trials (I2= 0%). The Fig. 5 illustrates the 





Although non-significant effect of Radical prosta-
tectomy was observed at 12 years follow-up on 
reducing all-cause mortality, we found a significant 
difference between treatments on prostate-cause 
mortality and distant metastases favoring radical 
prostatectomy at 12 years follow-up. In subgroup 
analysis of age, we found that, radical prostatec-
tomy, in younger patients<65 years had significant 
effect on prostate-cause mortality and distant me-
tastases rate while, there was no evidence in favor 
of a specific treatment for older patients, ≥65 
years. We found significant effect of urinary in-
continence and erectile dysfunction among partic-
ipants opted for WW strategy during 2 years.  
This is likely the first study which reports pooled 
clinical and functional results of recent random-
ized controlled trials comparing RP with WW 
strategy in treatment of clinically localized pros-
tate cancer patients. We found three trials with 
1568 participants. Moreover, included trials in 
meta-analysis would have adequate methodologi-
cal quality. We demonstrated how age could play 
substantial role in mortality rate of patients who 
underwent surgery. Non-significant effect of RP 
on reducing all-cause death among overall pa-
tients was observed. However, future reports of 
ongoing trials (21) and exploring the outcomes in 
broader time-point are required in this regard. In 
subgroup analysis of age<65 years, we even 
proved RP had significant effect on reducing dis-
ease-specific death and distant metastases, by in-
cluding ongoing trial’s findings. Functional out-
comes more than two items which pooled in this 
review should be analyzed and great attention 
ought to be paid to psychological status and 
health-related quality of life. Exploring impact of 
Gleason score and PSA level on clinical out-
comes so as to manage clinically localized pros-
tate cancer is useful; but SPCG-4 trial found no 
representative categories to explore role of these 
criteria. Race had impact on progression and dy-
ing from prostate cancer (37-39). One third of 
the participants in PIVOT were African-American 
increased risk of dying from prostate cancer. Pau-
city of data on diversities of ethnicity in SPCG-4 
trial prevented us from analyzing disease-specific 
death among different races. Furthermore, includ-
ed trials had different method regarding detection 
of patients. Majority of participants in PIVOT trial 
were detected through PSA screening (76%), while 
few participants in SPCG-4 trial were detected 
with PSA level (5%); and, most of them had clini-
cally detected prostate cancer. This diversity is im-
portant when some studies highlighted that lead 
time bias caused by PSA screening (40-42) may 
influence the time of occurrence of disease-




We found some evidence to recommend RP as a 
primary treatment for younger patients who suf-
fered from clinically localized prostate cancer at a 
12-year follow-up. However, including reports of 
ongoing trials and analyzing in broader time-
point may be allowed to precisely analyze clinical 
and functional outcomes. We found better sexual 
and urinary functions among patients who re-
ceived WW strategy during a 2-year follow-up. 
However, other variables such as psychological 
status, health-related quality of life, race differ-
ences and PSA screening should be substantiated 
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